A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
Status:
Terminated
Trial end date:
2020-01-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD)
in children and young adults with relapsed solid tumors, including recurrent malignant brain
tumors. All patients will receive BXQ-350 by intravenous (IV) infusion. The study is divided
into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to
determine the MTD. Part 2 will use the MTD to further assess the safety of BXQ-350 as well as
preliminary anti-tumor activity.